Form 4 for ADMA ADMA BIOLOGICS, INC.
Accepted 2025-02-21 00:00:00 ET · period of report 2025-02-19 · accession 0001140361-25-005534 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2025-02-21 | 2025-02-19 | ADMA | Grossman Adam S | Pres, CEO, Dir | A - Grant | $0.00 | +252.0K | 2.23M | +13% | $0 |
| D | 2025-02-21 | 2025-02-19 | ADMA | Grossman Adam S | Pres, CEO, Dir | A - Grant | $0.00 | +376.7K | 376.7K | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2025-02-19 | A | A | 252,022 | $0.00 | 2,226,686 | D | — | — | (F1) These shares represent restricted stock units ("RSUs") that will vest quarterly on each annual anniversary of the date of grant over four years in accordance with the ADMA Biologics, Inc. 2022 Equity Compensation Plan (the "Plan"), subject to the reporting person's continued service as of the applicable vesting date. (F4) (continued from footnote 3) and (vi) 790,876 shares of common stock owned by the reporting person, which reflects prior purchases and the prior net settlement upon vesting of previously granted RSUs after the withholding of shares to cover applicable taxes. (F2) Includes, as of the transaction date, (i) 252,022 unvested RSUs granted on February 19, 2025 and reported on this Form 4, subject to vesting as set forth in footnote (1); (ii) 557,728 RSUs granted on February 26, 2024, vesting quarterly on each annual anniversary of the date of grant over four years, subject to the reporting person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting; (iii) 430,272 unvested RSUs granted on March 6, 2023 that will vest quarterly on each annual anniversary of the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting; (F3) (continued from footnote 2) (iv) 150,000 unvested RSUs granted on March 7, 2022 that will vest quarterly on each annual anniversary of the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting; (v) 45,788 unvested RSUs granted on February 25, 2021, which will vest in equal quarterly installments on each annual anniversary of the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date, and will be settled into common stock upon vesting; |
| 2 | Derivative | Stock Option (right to buy) | 2025-02-19 | A | A | 376,744 | $0.00 | 376,744 | D | $16.07 · — to 2035-02-19 | 376,744 Common Stock | (F7) The options vest over four years with 25% of the shares of common stock underlying the option vesting on the one-year anniversary of the date of grant and the remaining 75% of such shares vesting monthly in equal installments over the next three years, becoming fully vested on February 19, 2029 in accordance with the Plan. |